Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

EHA 2024

Leukemia

APOLLO: Superior outcomes with ATRA-ATO regimen in high-risk acute promyelocytic leukemia

Leukemia

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

Haematologica

Sobas MA, Turki AT, Ramiro AV, Sánchez AH, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L

doi: 10.3324/haematol.2024.285805

Lung, Respiratory and Thoracic Cancer

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Lung Cancer

Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H

doi: 10.1016/j.lungcan.2024.108056

Skin Cancer

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

Eur J Cancer

Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS

doi: 10.1016/j.ejca.2024.115171

Leukemia

Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia

Leukemia

Orvain C, Milano F, Rodríguez-Arbolí E, Othus M, Petersdorf EW, Sandmaier BM, Appelbaum FR, Walter RB

doi: 10.1038/s41375-024-02497-z

Myeloproliferative Neoplasms (MPNs)

Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study

Leukemia

England JT, Szuber N, Sirhan S, Dunne T, Cerquozzi S, Hill M, Villeneuve PJA, Ho JM, Sadikovic B, Bhai P, Krishnan N, Dowhanik S, Hillis C, Capo-Chichi JM, Tsui H, Cheung V, Gauthier K, Sibai H, Davidson MB, Bankar A, Kotchetkov R, Gupta V, Maze D

doi: 10.1038/s41375-024-02155-4

Skin Cancer

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

Eur J Cancer

Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA

doi: 10.1016/j.ejca.2024.115119

Leukemia

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Blood Cancer J

Schmälter AK, Ngoya M, Galimard JE, Bazarbachi A, Finke J, Kröger N, Bornhäuser M, Stelljes M, Stölzel F, Tischer J, Schroeder T, Dreger P, Blau IW, Savani B, Giebel S, Esteve J, Nagler A, Schmid C, Ciceri F, Mohty M

doi: 10.1038/s41408-024-01060-4

Skin Cancer

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma

J Clin Oncol

Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi FS

doi: 10.1200/JCO.24.00400

Related content

APOLLO: Superior outcomes with ATRA-ATO regimen in high-risk acute promyelocytic leukemia

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia

Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma